Private Advisor Group LLC Raises Stock Holdings in ImmunityBio, Inc. $IBRX

Posted by Brian Himes on Jul 5th, 2026

Private Advisor Group LLC increased its stake in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 923.5% during the 1st quarter, Holdings Channel reports. The firm owned 1,648,556 shares of the company’s stock after purchasing an additional 1,487,482 shares during the quarter. Private Advisor Group LLC’s holdings in ImmunityBio were worth $12,644,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IBRX. Mariner LLC lifted its position in ImmunityBio by 10.5% during the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock valued at $35,000 after purchasing an additional 1,689 shares during the last quarter. Sanctuary Advisors LLC raised its position in shares of ImmunityBio by 6.9% during the 4th quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company’s stock valued at $59,000 after buying an additional 1,918 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in shares of ImmunityBio by 8.6% during the 4th quarter. Sequoia Financial Advisors LLC now owns 28,783 shares of the company’s stock valued at $57,000 after buying an additional 2,271 shares in the last quarter. Mutual Advisors LLC lifted its holdings in shares of ImmunityBio by 9.0% during the 4th quarter. Mutual Advisors LLC now owns 30,200 shares of the company’s stock worth $60,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of ImmunityBio by 4.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company’s stock worth $150,000 after acquiring an additional 3,280 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $9.44 on Friday. The firm’s fifty day moving average is $7.71 and its 200 day moving average is $6.74. ImmunityBio, Inc. has a 52 week low of $1.95 and a 52 week high of $12.43. The company has a market cap of $9.89 billion, a price-to-earnings ratio of -11.11 and a beta of 0.01.

ImmunityBio (NASDAQ:IBRX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The business had revenue of $44.21 million for the quarter, compared to analyst estimates of $43.07 million. Equities research analysts anticipate that ImmunityBio, Inc. will post -0.31 earnings per share for the current year.

Insider Activity

In other news, Director Barry J. Simon sold 25,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the sale, the director directly owned 2,802,788 shares in the company, valued at approximately $22,085,969.44. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christobel Selecky sold 95,722 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $9.01, for a total value of $862,455.22. Following the completion of the sale, the director directly owned 32,173 shares in the company, valued at $289,878.73. The trade was a 74.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 144,755 shares of company stock valued at $1,233,832. Insiders own 66.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of ImmunityBio in a research report on Tuesday, June 2nd. BTIG Research reaffirmed a “buy” rating and set a $12.00 price target on shares of ImmunityBio in a research note on Thursday, May 21st. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, April 14th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

Get Our Latest Stock Analysis on IBRX

ImmunityBio Company Profile

(Free Report)

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.